Literature DB >> 24997091

Pregnancy and postpartum infective endocarditis: a systematic review.

Kalie Y Kebed1, Kalkidan Bishu2, Raed I Al Adham3, Larry M Baddour4, Heidi M Connolly2, Muhammad R Sohail4, James M Steckelberg4, Walter R Wilson4, Mohammad H Murad5, Nandan S Anavekar2.   

Abstract

The objective of this review was to describe the clinical characteristics, risk factors, and outcomes of infective endocarditis (IE) in pregnancy and the postpartum period. We conducted a systematic review of Ovid MEDLINE, Ovid Embase, Web of Science, and Scopus from January 1, 1988, through October 31, 2012. Included studies reported on women who met the modified Duke criteria for the diagnosis of IE and were pregnant or postpartum. We included 72 studies that described 90 cases of peripartum IE, mostly affecting native valves (92%). Risk factors associated with IE included intravenous drug use (14%), congenital heart disease (12%), and rheumatic heart disease (12%). The most common pathogens were streptococcal (43%) and staphylococcal (26%) species. Septic pulmonary, central, and other systemic emboli were common complications. Of the 51 pregnancies, there were 41 (80%) deliveries with survival to discharge, 7 (14%) fetal deaths, 1 (2%) medical termination of pregnancy, and 2 (4%) with unknown status. Maternal mortality was 11%. Infective endocarditis is a rare, life-threatening infection in pregnancy. Risk factors are changing with a marked decrease in rheumatic heart disease and an increase in intravenous drug use. The cases reported in the literature were commonly due to streptococcal organisms, involved the right-sided valves, and were associated with intravenous drug use.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24997091     DOI: 10.1016/j.mayocp.2014.04.024

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  24 in total

1.  Peri-procedural antibiotic prophylaxis in ventricular septal defect: a case study to re-visit guidelines.

Authors:  Nadish Garg; Mannu Nayyar; Rami N Khouzam; Salem A Salem; Devarshi Ardeshna
Journal:  Ann Transl Med       Date:  2018-01

Review 2.  Management of the Cardiovascular Complications of Substance Use Disorders During Pregnancy.

Authors:  P Kaitlyn Edelson; Sarah N Bernstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-22

Review 3.  Staphylococcus Aureus Infective Endocarditis: JACC Patient Pathways.

Authors:  Julia Grapsa; Christopher Blauth; Y S Chandrashekhar; Bernard Prendergast; Blair Erb; Michael Mack; Valentin Fuster
Journal:  JACC Case Rep       Date:  2021-11-15

4.  Postpartum infective endocarditis with Enterococcus faecalis after vaginal delivery.

Authors:  İbrahim Etem Dural; Serkan Gökaslan; Zafer Yalım; Uğur Aksu; Ömer Faruk Yılmaz; İbrahim Ersoy; Fehim Can Sevil
Journal:  Anatol J Cardiol       Date:  2021-12       Impact factor: 1.596

5.  Peripartum native valve endocarditis without underlying risk factors.

Authors:  Riju Nair; Subbaiyan Kumar; Rajan Mani
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2021-02-15

6.  [Infective endocarditis in pregnancy: A case report].

Authors:  B Yu; Y Y Zhao; Z Zhang; Y Q Wang
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2022-06-18

7.  Streptococcus oralis endocarditis leading to central nervous system infection in pregnancy.

Authors:  S Wydall; F Durrant; J Scott; K Cheesman
Journal:  Anaesth Rep       Date:  2021-10-07

Review 8.  Pregnancy and cardiovascular disease.

Authors:  Karishma P Ramlakhan; Mark R Johnson; Jolien W Roos-Hesselink
Journal:  Nat Rev Cardiol       Date:  2020-06-09       Impact factor: 32.419

9.  Multivalvular infective endocarditis in pregnancy presenting with septic pulmonary emboli.

Authors:  Nicola English; Polly Weston
Journal:  BMJ Case Rep       Date:  2015-05-07

10.  Maternal and Fetal Outcomes Associated With Infective Endocarditis in Pregnancy.

Authors:  Michael M Dagher; Emily M Eichenberger; Kateena L Addae-Konadu; Sarah K Dotters-Katz; Celia L Kohler; Vance G Fowler; Jerome J Federspiel
Journal:  Clin Infect Dis       Date:  2021-11-02       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.